JP2004520287A5 - - Google Patents

Download PDF

Info

Publication number
JP2004520287A5
JP2004520287A5 JP2002545557A JP2002545557A JP2004520287A5 JP 2004520287 A5 JP2004520287 A5 JP 2004520287A5 JP 2002545557 A JP2002545557 A JP 2002545557A JP 2002545557 A JP2002545557 A JP 2002545557A JP 2004520287 A5 JP2004520287 A5 JP 2004520287A5
Authority
JP
Japan
Prior art keywords
composition
antibody
immunospecific
composition according
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002545557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520287A (ja
Filing date
Publication date
Priority claimed from US09/724,620 external-priority patent/US6572856B1/en
Application filed filed Critical
Publication of JP2004520287A publication Critical patent/JP2004520287A/ja
Publication of JP2004520287A5 publication Critical patent/JP2004520287A5/ja
Pending legal-status Critical Current

Links

JP2002545557A 2000-11-28 2001-11-28 抗Ｃ３ｂ（ｉ）抗体を用いる癌の予防および治療方法 Pending JP2004520287A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,620 US6572856B1 (en) 1998-09-10 2000-11-28 Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
PCT/US2001/044813 WO2002043570A2 (en) 2000-11-28 2001-11-28 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2004520287A JP2004520287A (ja) 2004-07-08
JP2004520287A5 true JP2004520287A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=24911153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002545557A Pending JP2004520287A (ja) 2000-11-28 2001-11-28 抗Ｃ３ｂ（ｉ）抗体を用いる癌の予防および治療方法

Country Status (6)

Country Link
US (1) US6572856B1 (cg-RX-API-DMAC7.html)
EP (1) EP1355563A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004520287A (cg-RX-API-DMAC7.html)
AU (1) AU2002236519A1 (cg-RX-API-DMAC7.html)
CA (1) CA2429987A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002043570A2 (cg-RX-API-DMAC7.html)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022788A1 (en) 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
CN1218182C (zh) * 1999-05-28 2005-09-07 干细胞技术公司 利用免疫玫瑰花结分离细胞的方法
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP2003525061A (ja) * 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
CA2417432C (en) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2003016470A2 (en) * 2001-08-10 2003-02-27 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
EP1483383A4 (en) * 2002-02-15 2007-10-24 Cygene Inc METHODS AND COMPOSITIONS FOR THE CLEANING OF PATHOGENS IN VIVO
WO2003106695A2 (en) * 2002-06-13 2003-12-24 Cygene, Inc. Methods and compositions for in vivo clearance of pathogens
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AT413487B (de) * 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
US7550256B2 (en) * 2002-12-13 2009-06-23 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2003302986A1 (en) * 2002-12-13 2004-07-09 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
AU2003300676A1 (en) * 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004080819A2 (en) * 2003-03-14 2004-09-23 Aurelium Biopharma Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US8420783B2 (en) * 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US20090192077A1 (en) * 2005-04-15 2009-07-30 Shizuko Sei North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus
US8524453B2 (en) * 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
IN2012DN03354A (cg-RX-API-DMAC7.html) 2009-12-02 2015-10-23 Immunomedics Inc
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
US8791121B2 (en) 2010-08-12 2014-07-29 New York University Oligooxopiperazines and methods of making and using them
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013123511A1 (en) 2012-02-16 2013-08-22 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015105973A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
EP3571221A2 (en) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Cell surface conjugates and related cell compositions and methods
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
WO2025143000A1 (ja) * 2023-12-27 2025-07-03 東亞合成株式会社 Ｃ３ ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
FR2660069B1 (fr) 1990-03-20 1994-03-04 Recherche Developpement Activ Co Procede pour la mise en evidence de la capacite d'un spermatozouide a subir la reaction acrosomale.
US5322699A (en) * 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
WO1996037234A1 (en) 1995-05-23 1996-11-28 Thomas Jefferson University Intracellular immunization
CA2251344A1 (en) 1996-04-09 1997-10-16 Bard Diagnostic Sciences, Inc. Methods and compositions for screening for or modulating a tumor associated antigen
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
EP0972200A1 (en) 1997-03-06 2000-01-19 Bion Diagnostic Sciences, Inc. Screening and treatment using complement regulator or receptor proteins
JP2002524533A (ja) * 1998-09-10 2002-08-06 ザ ユニヴァーシティー オブ ヴァージニア パテント ファウンデーション 癌細胞に診断薬及び治療薬をデリバリーするためのＣ３ｂ（ｉ）に対する抗体
WO2001058483A2 (en) * 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES

Similar Documents

Publication Publication Date Title
Stein et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
Winer et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate
Shaw et al. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses
Elkins et al. FcRL5 as a target of antibody–drug conjugates for the treatment of multiple myeloma
Frankel et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia
CN110494448B (zh) 包含抗-ly75抗体的医药组合
NO20040976L (no) Humane CDR-podede antistoffer og antistoff-fragmenter derav.
RU2004127458A (ru) Анти-cd20 антитела, их гибридные белки и способы их использования
JP2014512812A5 (cg-RX-API-DMAC7.html)
EP1485130A4 (en) REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
EA200602183A1 (ru) Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
JP2011514146A5 (cg-RX-API-DMAC7.html)
ATE553131T1 (de) Humane monoklonale antikörper gegen dendritische zellen
EP3416984A1 (en) Chimeric canine anti-cd20 antibody
EP3814379A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
Bernardo et al. Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice
Valent et al. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues
ES2338919T3 (es) Anticuerpos anti-receptor ccr7 para el tratamiento del cancer.
Maaland et al. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Du et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
US11890348B2 (en) Localized delivery of anti-fugetactic agent for treatment of cancer
Ahmed et al. The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma
KR102912346B1 (ko) 약학적 배합물
Liu et al. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells